Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses.
Hospira, Inc., a leading provider of clinical information and medication delivery technologies, today announced a study showing how the TheraDoc clinical surveillance system helped clinicians at Memorial Hospital Miramar reduce catheter-related infections, which correlated with an increase in infection-control interventions.
BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
CIDRAP News examines a recently-released WHO report on how donor countries and organizations have responded to the needs of developing countries during the H1N1 (swine flu) pandemic. In September, the WHO estimated the "64 'least-resourced countries' needed a total of $1.48 billion of aid for vaccine, medicines and supplies, laboratory and surveillance services, communications capacity, and other activities to respond to the pandemic," according to the news service.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.
The independent team of health experts responsible for reviewing the WHO's response to H1N1 (swine flu) wrapped up a second round of public hearings on Friday, "during which members heard testimony from widely divergent groups, from health officials to some of its most public critics," CIDRAP News reports.
Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope are excited to announce that the company has secured a new business partner in Ethiopia through which Mellow Hope will distribute biomedical vaccines.
Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Infectious Diseases, 3rd Edition.
IBM and the University of Missouri today announced a life sciences research initiative using IBM high performance computing technologies to advance the school's bioinformatics research projects. The goal of the initiative is to develop a first-of-a-kind cloud computing environment for genomics research collaboration at a regional level.
Recent disease events such as SARS, H1N1 and avian influenza, and haemorrhagic fevers have focussed policy and public concern as never before on epidemics and so-called 'emerging infectious diseases'. Understanding and responding to these often unpredictable events have become major challenges for local, national and international bodies.
Ecolab Inc. today announced the launch of Virasept, Ecolab's first ready-to-use (no mixing required) hard surface disinfectant approved by the U.S. Environmental Protection Agency to be effective against Clostridium difficile spores.
BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.
Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work was conducted by researchers at Theraclone Sciences, with collaborators at University of Wisconsin-Madison, University of Tokyo and Johns Hopkins University; and is reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.
UCI Medical Affiliates, Inc. today announced that it had filed its Quarterly Reports on Form 10-Q for the quarters ended December 31, 2009 and March 31, 2010.
Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.
BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.
World Customs Organization Secretary General Kunio Mikuriya on Thursday signed a declaration vowing his group's commitment to crack down on the counterfeit drug industry, PBS NewsHour's "The Rundown" blog reports. The piece examines the growing threat of counterfeit medications worldwide and efforts to clamp down on the distribution of such drugs (Miller, 6/24).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.